Literature DB >> 20203465

Case report: acute renal failure after administering intravenous immunoglobulin.

Aaron Graumann1, Edward T Zawada.   

Abstract

We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG). She had been receiving monthly transfusions of IVIG, but this time had received daily infusions for 5 days rather than 1 day. She had received this same dose in the past without incident. Her history was significant for coronary artery disease, atrial fibrillation, deep venous thrombosis, pulmonary embolism, chronic steroid use, and recurrent urinary tract infection. On examination, she was slightly confused, mildly dehydrated, had a grade II systolic ejection murmur along the upper left sternal border, had bilateral and symmetric mild weakness of the upper and lower extremities, and exhibited mild edema of the lower extremities. Before transfer from the emergency room, she was found to have an elevated serum urea nitrogen and creatinine of 55 and 5.8 mg/dL (19.6 mmol/L and 512.7 micromol/L, respectively). Creatinine 8 days earlier was 0.9 mg/dL (79.6 micromol/L). The hospital course of the acute renal failure is presented with a review of the literature on cases of acute renal failure after IVIG.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203465     DOI: 10.3810/pgm.2010.03.2131

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  3 in total

1.  Intravenous immunoglobulin in pediatrics: A review.

Authors:  A N Prasad; Sanjay Chaudhary
Journal:  Med J Armed Forces India       Date:  2013-08-06

2.  Intravenous immunoglobulin-associated renal failure in a patient with post-transfusion purpura.

Authors:  Sujith V Cherian; Subhraleena Das; Amarinder S Garcha; Divey Manocha; Nitish Kosaraju
Journal:  Ann Saudi Med       Date:  2012-07-01       Impact factor: 1.526

3.  Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations.

Authors:  Roger H Kobayashi; Michael T Rigas
Journal:  Am J Health Syst Pharm       Date:  2022-08-19       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.